Compare Shandong Weigao Group Medical Polymer Co. Ltd. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 20.01%
- Healthy long term growth as Net Sales has grown by an annual rate of 27.91%
- Company has very low debt and has enough cash to service the debt requirements
2
Negative results in Dec 25
3
With ROE of 1.83%, it has a Very Expensive valuation with a 0.85 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
HKD 15,738 Million ()
46.00
NA
6.60%
-0.17
1.80%
0.59
Revenue and Profits:
Net Sales:
1,544 Million
(Quarterly Results - Dec 2013)
Net Profit:
-502 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.94%
0%
27.94%
6 Months
117.5%
0%
117.5%
1 Year
216.36%
0%
216.36%
2 Years
304.65%
0%
304.65%
3 Years
386.71%
0%
386.71%
4 Years
427.27%
0%
427.27%
5 Years
388.22%
0%
388.22%
Shandong Weigao Group Medical Polymer Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
27.91%
EBIT Growth (5y)
23.38%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
0.19
Tax Ratio
33.01%
Dividend Payout Ratio
45.46%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
15.45%
ROE (avg)
20.01%
Valuation key factors
Factor
Value
P/E Ratio
46
Industry P/E
Price to Book Value
0.85
EV to EBIT
13.52
EV to EBITDA
11.46
EV to Capital Employed
0.81
EV to Sales
3.06
PEG Ratio
NA
Dividend Yield
4.65%
ROCE (Latest)
6.02%
ROE (Latest)
1.83%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.01%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'13 - YoY
Dec'13
Dec'12
Change(%)
Net Sales
1,544.20
1,029.30
50.02%
Operating Profit (PBDIT) excl Other Income
370.70
251.20
47.57%
Interest
2.20
4.10
-46.34%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-501.80
285.60
-275.70%
Operating Profit Margin (Excl OI)
195.30%
203.10%
-0.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2013 is 50.02% vs -1.52% in Dec 2012
Consolidated Net Profit
YoY Growth in quarter ended Dec 2013 is -275.70% vs -91.66% in Dec 2012
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
14,520.60
14,189.30
2.33%
Operating Profit (PBDIT) excl Other Income
3,104.10
3,593.50
-13.62%
Interest
277.50
270.60
2.55%
Exceptional Items
38.20
29.20
30.82%
Consolidate Net Profit
1,855.30
2,344.90
-20.88%
Operating Profit Margin (Excl OI)
140.50%
179.40%
-3.89%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 2.33% vs -2.94% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -20.88% vs 2.93% in Dec 2024
About Shandong Weigao Group Medical Polymer Co. Ltd. 
Shandong Weigao Group Medical Polymer Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






